Home > Insider Trading > Filing (0001493152-20-009217)

Filing Details

Accession Number:: 0001493152-20-009217
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-15 18:16:57
Reporting Period:: 2020-05-05

Accepted Time:: 2020-05-15 18:16:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1327273	Lyra Therapeutics Inc.	LYRA	Surgical & Medical Instruments & Apparatus (3841)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1752427	Soleus Private Equity Fund I, L.p.	104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No
1786724	Soleus Capital, Llc	104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No
1812273	Soleus Private Equity Gp I, Llc	104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No
1812274	Soleus Pe Gp I, Llc	104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No
1812275	Soleus Capital Master Fund, L.p.	104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No
1812276	Soleus Capital Group, Llc	104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No
1812305	Guy Levy	C/O Soleus Private Equity Gp I, Llc 104 Field Point Road, 2Nd Floor Greenwich CT 06830	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-05-05	338,330	$0.00	338,330	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-05-05	104,608	$0.00	442,948	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-05-05	31,382	$8.63	474,330	No	4	X	Indirect	See footnote
Common Stock	Disposition	2020-05-05	16,909	$16.00	457,421	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2020-05-05	155,000	$16.00	155,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	X	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2020-05-05	11,666,666	$0.00	338,330	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2020-05-05	3,607,224	$0.00	104,608	$0.00
Common Stock	Common Stock Warrant	Disposition	2020-05-05	31,382	$0.00	31,382	$8.63

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
		No	4	C	Indirect
		No	4	C	Indirect
2020-01-27	2030-01-27	No	4	X	Indirect

Footnotes

The securities reported in this row are owned directly by Soleus Private Equity Fund I, L.P. ("Soleus PE"). Soleus Private Equity GP I, LLC ("Soleus GP") is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP I, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP I, LLC. Each of Mr. Guy Levy, Soleus PE GP I, LLC and Soleus GP disclaims beneficial ownership of these securities held by Soleus PE and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
The securities reported in this row are held by Soleus Capital Master Fund, L.P. ("Master Fund"). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
On May 5, 2020, Soleus PE exercised a warrant to purchase an aggregate of 31,382 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 16,909 of the warrant shares to pay the exercise price and issued the remaining 14,473 shares of common stock to Soleus PE. The Issuer also paid $13.77 to Soleus PE in lieu of a fractional share.
Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering.